Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group

The New England Journal of Medicine
R S SchwartzM J Inwood

Abstract

Current treatment of hemophilia A, a hereditary disorder affecting approximately 1 in 10,000 males, relies on plasma-derived factor VIII concentrates. We tested the safety and efficacy of a recombinant factor VIII preparation for the treatment of this disorder. We conducted the investigation in three stages: comparing the pharmacokinetics of plasma-derived and recombinant factor VIII, assessing the efficacy of recombinant factor VIII for home therapy, and assessing its efficacy for major surgical procedures and hemorrhage. A total of 107 subjects with hemophilia, 20 of whom had not been treated previously, enrolled in the investigation. The in vivo recovery and elimination half-lives of recombinant factor VIII equaled or exceeded those of plasma-derived factor VIII. Seventy-six subjects participated in a home-treatment program, using recombinant factor VIII for 69 to 807 days (median, 618); home diaries of 56 subjects treated for 5 months were analyzed. Of 540 bleeding episodes, 399 (73.9 percent) required only one treatment with recombinant factor VIII. The projected annual consumption of recombinant factor VIII was similar to that of plasma-derived factor VIII concentrate. Twenty-six subjects received recombinant factor VIII ...Continue Reading

References

Jan 19, 1989·The New England Journal of Medicine·G C WhiteC B Shoemaker
Jun 16, 1989·JAMA : the Journal of the American Medical Association·G F PierceC M Kessler
Dec 1, 1987·Clinical Pharmacokinetics·A MessoriP L Ferrini
Dec 26, 1974·The New England Journal of Medicine·P H Levine
Mar 11, 1982·The New England Journal of Medicine·L M Aledort

❮ Previous
Next ❯

Citations

Jan 1, 1993·Journal of Clinical Apheresis·P H Levine
Aug 21, 1992·Pharmaceutisch Weekblad. Scientific Edition·P Vermeij
Jan 6, 2004·International Journal of Hematology·A YoshiokaUNKNOWN Kogenate Post-Marketing Surveillance Study Group
Nov 3, 2009·International Journal of Hematology·Jeanne M Lusher, Inge Scharrer
May 23, 1992·Lancet·N Ciavarella, M Schiavoni
Apr 1, 1992·Transfusion Medicine Reviews·G H GroweI Scarth
Oct 1, 1992·Transfusion Medicine Reviews·J R Dillon
May 7, 1998·Transfusion Science·G C WhiteH R Roberts
Apr 25, 2001·Clinical and Laboratory Haematology·G EmilienC Casimir
Dec 21, 2000·Haemophilia : the Official Journal of the World Federation of Hemophilia·I ScharrerE Kellermann
May 23, 1991·The New England Journal of Medicine·H Kawane
Mar 19, 1992·The New England Journal of Medicine·B Furie, B C Furie
Jun 9, 2001·The New England Journal of Medicine·P M Mannucci, E G Tuddenham
Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M S HershfieldS A Short
Feb 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·V J DwarkiL K Cohen
Oct 21, 2006·Current Opinion in Hematology·Shannon L Meeks, Cassandra D Josephson
Jan 1, 1994·Vox Sanguinis·P M Mannucci
Aug 19, 1995·BMJ : British Medical Journal·E G Tuddenham, M Laffan
Sep 30, 2008·Blood·Christine L Kempton, Gilbert C White
Aug 24, 2006·International Journal of Hematology·A YoshiokaUNKNOWN Kogenate Post-Marketing Surveillance Study Group
Dec 12, 2001·Clinical Pharmacokinetics·S Björkman, E Berntorp
Feb 16, 2011·Drugs·Trisha Wong, Michael Recht
Nov 5, 2009·Clinical Medicine : Journal of the Royal College of Physicians of London·Christine A Lee
May 5, 2007·Expert Opinion on Biological Therapy·Yesim Dargaud, Claude Negrier
Apr 27, 2013·Journal of Pharmaceutical Sciences·Matthew P KosloskiSathy V Balu-Iyer
Oct 27, 2009·Journal of the American College of Surgeons·Sharif Al-Ruzzeh, Jose L Navia
Jun 11, 2005·Journal of Thrombosis and Haemostasis : JTH·D B Brettler
Jul 20, 2004·British Journal of Haematology·Alessandro GringeriUNKNOWN ReFacto-AICE Study Group
Feb 21, 2006·British Journal of Haematology·Paula H B Bolton-Maggs
Apr 20, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·J M Lusher
Oct 3, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·M MorfiniA Iorio
Sep 1, 1992·Blood Reviews·M Winter
Jun 1, 1996·Baillière's Clinical Haematology·J M Lusher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.